Riluzole

證據等級: L5

預測適應症: 10 個

Riluzole: From Amyotrophic Lateral Sclerosis to Bilateral Parasagittal Parieto-Occipital Polymicrogyria

One-Sentence Summary

Riluzole is a glutamate antagonist established as the principal pharmacological treatment for amyotrophic lateral sclerosis (ALS), where it modestly prolongs survival by reducing excitotoxic motor neuron death. The TxGNN model predicts it may have utility in Bilateral Parasagittal Parieto-Occipital Polymicrogyria (BPPP), a rare structural cortical malformation disorder characterised by epilepsy and cognitive impairment. Currently, 0 clinical trials and 0 publications directly support this specific repurposing direction, and the recommendation is Hold.

Quick Overview

Item	Content
Original Indication	Amyotrophic Lateral Sclerosis (ALS)
Predicted New Indication	Bilateral Parasagittal Parieto-Occipital Polymicrogyria
TxGNN Prediction Score	99.99%
Evidence Level	L5
UK Market Status	Not marketed (no MHRA licence recorded in current data pack — see note under UK Market Information)
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Riluzole’s mechanism of action centres on inhibition of pre-synaptic glutamate release via voltage-gated sodium channel blockade, coupled with reduction of NMDA/AMPA receptor-mediated excitatory neurotransmission. This anti-excitotoxic profile forms the basis for its established efficacy in ALS, where glutamate excitotoxicity is a central pathophysiological driver of progressive motor neuron death — a relationship confirmed by the landmark 1994 Phase 3 RCT (Bensimon et al., NEJM).

Bilateral parasagittal parieto-occipital polymicrogyria is a rare neuronal migration disorder in which abnormal cortical folding creates a structurally malformed parieto-occipital cortex. The primary clinical manifestations are epilepsy and cognitive impairment. A narrow theoretical rationale exists for the TxGNN prediction: cortical hyperexcitability — partly mediated by dysregulated glutamatergic signalling — is recognised as a contributor to the epileptic phenotype associated with cortical malformations. In this limited sense, riluzole’s anti-glutamatergic action could theoretically modulate seizure burden.

Nonetheless, BPPP represents an irreversible structural lesion; no pharmacological agent can reverse the underlying malformation. Riluzole has no established or exploratory role in cortical dysplasia or neuronal migration disorders, and there is no preclinical evidence in relevant animal or cell models. The high TxGNN prediction score most likely reflects a knowledge graph artefact — shared network pathways relating to cortical excitability — rather than genuine clinical repurposing feasibility. This prediction should be treated as a computational hypothesis only, with no actionable near-term clinical pathway.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

UK Market Information

The current data pack records riluzole as having no MHRA marketing authorisations in the United Kingdom (market status: not marketed; total licences: 0). This is highly likely to represent a data gap in the evidence pipeline rather than a true regulatory absence.

Riluzole (Rilutek® 50 mg film-coated tablets; Teglutik® 5 mg/ml oral suspension) is understood to hold current MHRA product licences for the treatment of ALS in the United Kingdom. NICE technology appraisal TA20 (2001) recommended riluzole as a treatment option for ALS, and it appears in the BNF under nervous system — motor neurone disease. Clinicians should verify current authorisation status directly via the MHRA Product Licence register and retrieve the SmPC before any prescribing or commissioning decision.

Safety Considerations

Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.

Conclusion and Next Steps

Decision: Hold

Rationale: Bilateral parasagittal parieto-occipital polymicrogyria is a structural, irreversible cortical malformation with no pharmacologically modifiable underlying pathology. There is no clinical, observational, or preclinical evidence to support riluzole use in this condition, and the L5 evidence classification (model prediction only) precludes any further advancement through the repurposing pipeline without foundational supporting data.

To proceed, the following is needed:

Confirm current MHRA product licence status for riluzole and retrieve the UK SmPC and BNF entry
Retrieve formal mechanism of action data from DrugBank (currently not obtained — data gap DG002)
Commission or identify preclinical evidence (in vitro cortical hyperexcitability models or relevant animal models of cortical dysplasia) examining riluzole’s effect on malformation-associated epilepsy
Obtain independent expert neurological review (epilepsy and neurogenetics) to assess whether a structured research question is scientifically warranted before any further resource is committed

This report is generated for research purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any therapeutic application. Healthcare professionals should refer to the SmPC, BNF, and relevant NICE guidance before making prescribing decisions.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.